CliffBio
small molecule

YUTREPIA

TREPROSTINIL SODIUM

Loss of exclusivityMay 2037latest FDA-listed patent expiry
CompanyLiquidia Technologies →See this company's full patent-cliff portfolio

Drug detail

Brand nameYUTREPIA
Active ingredientTREPROSTINIL SODIUM
StrengthEQ 0.053MG BASE/INH
Dosage formPOWDER
RouteINHALATION
ModalitySmall molecule
FDA approvalMay 2025
Marketing statusRX

Listed patents

PatentExpiresType
11712442May 2037use U-4200
10898494May 2037use U-4200
11660304May 2037use U-4200
11744835May 2037product
12390475May 2037product
11744836May 2037product

Regulatory exclusivity

CodeExpires
NPMay 2028

More from Liquidia Technologies

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.